Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 31, 2024, titled "Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 31, 2024, titled "Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024".